IMDNA develops cardiovascular research assays for studying cardiac stress and injury, atherosclerosis, vascular inflammation, endothelial biology, myocardial remodeling, fibrosis, oxidative and metabolic stress, angiogenesis, thrombosis-associated pathways, and treatment-related molecular changes.
Research programs can integrate RT-qPCR/qPCR for targeted gene-expression or nucleic-acid studies, ELISA for focused quantitative protein biomarker research, and multiplex bead-based immunoassays for simultaneous cytokine, chemokine, and soluble-protein profiling. Each platform is selected according to the analyte and research question rather than treated as interchangeable.
Research cardiomyocyte stress, injury, hypertrophy, extracellular-matrix remodeling, and heart-failure-associated pathways.
Investigate endothelial activation, vascular inflammation, lipid handling, plaque-associated biology, and vascular dysfunction.
Study cytokine, chemokine, leukocyte, macrophage, oxidative-stress, and tissue-repair pathways.
Combine RT-qPCR, ELISA, and multiplex protein measurements when scientifically justified.
Support candidate biomarker verification, longitudinal profiling, mechanistic studies, and experimental treatment-response research.
Cardiovascular disease is not a single molecular entity. NHLBI defines heart and vascular disease broadly across conditions such as coronary heart disease, myocardial infarction, heart failure, arrhythmias, hypertension, congenital heart disease, vascular disease, and stroke. At the molecular level, these disorders can involve overlapping combinations of cardiomyocyte stress, vascular dysfunction, inflammation, thrombosis, metabolism, fibrosis, endothelial signaling, and tissue remodeling.
Research may examine cardiomyocyte stress, contractile and structural genes, hypertrophic responses, ischemic injury, metabolic adaptation, neurohormonal signaling, and molecular remodeling.
Endothelial activation, vascular tone, permeability, leukocyte adhesion, oxidative stress, angiogenic signaling, and arterial remodeling are major mechanistic themes across atherosclerotic and nonatherosclerotic cardiovascular research.
AHA cardiovascular–kidney–metabolic frameworks emphasize inflammation, oxidative stress, metabolic dysfunction, and vascular dysfunction as interconnected processes that can contribute to cardiovascular disease development and progression.
Cardiac fibrosis is heterogeneous and can reflect fibroblast activation, altered collagen turnover, inflammatory cues, mechanical stress, and TGF-β-associated signaling. Fibrosis should therefore be studied as a pathway and tissue-remodeling process rather than inferred from one transcript alone.
Research assays can be assembled as pathway modules rather than rigid disease panels. This allows target selection to remain linked to a defined biological hypothesis.
Investigate myocardial stress, ischemic responses, hypoxia-associated signaling, injury-response pathways, and cardiomyocyte adaptation.
Study cytokine, chemokine, monocyte/macrophage, leukocyte-recruitment, and inflammatory signaling associated with vascular or myocardial injury.
Explore endothelial nitric-oxide biology, vasoregulatory signaling, adhesion molecules, permeability, oxidative stress, and vascular inflammatory activation.
Investigate lipid uptake, cholesterol transport, lipoprotein-associated pathways, foam-cell biology, vascular inflammation, and plaque-associated molecular responses.
Study TGF-β-associated signaling, fibroblast activation, collagen turnover, extracellular-matrix remodeling, and matrix metalloproteinase biology.
Explore redox regulation, ROS-generating pathways, antioxidant responses, mitochondrial stress, and cardiometabolic adaptation.
Research selected coagulation, platelet, endothelial, fibrinolytic, and thrombo-inflammatory pathways while distinguishing molecular expression from functional coagulation assays.
Investigate vascular-growth signaling, endothelial responses, microvascular remodeling, and tissue adaptation to ischemia or injury.
Study contractile, sarcomeric, cytoskeletal, calcium-handling, and structural remodeling programs in cardiac models.
Explore natriuretic-peptide-related, renin–angiotensin–aldosterone, endothelin, and other study-specific neurohormonal pathways.
Compare inflammatory, apoptotic, survival, reparative, and regenerative programs after myocardial or vascular injury.
Profile molecular or protein changes across untreated controls, drug exposures, device-related models, dose levels, time points, and responder groups.
These research areas illustrate how assay development can be tailored to disease biology without implying that any one gene-expression signature is diagnostic or universally applicable.
Study lipid biology, endothelial activation, vascular inflammation, macrophage responses, plaque-associated signaling, oxidative stress, and thrombosis-related pathways.
Investigate ischemia, inflammatory injury, cardiomyocyte stress, tissue repair, scar formation, extracellular-matrix remodeling, and post-infarction recovery.
Study neurohormonal activation, myocardial stress, hypertrophy, fibrosis, inflammation, metabolic dysfunction, and chamber remodeling.
Investigate vascular tone, endothelial dysfunction, oxidative stress, smooth-muscle responses, remodeling, and pressure-overload-associated cardiac pathways.
Research structural, genetic, inflammatory, metabolic, mitochondrial, fibrotic, and stress-response pathways in investigator-defined cardiomyopathy models.
Study endothelial biology, arterial remodeling, ischemia, vascular inflammation, thrombosis, wound-healing responses, and angiogenic adaptation.
Investigate structural remodeling, fibrosis, inflammatory signaling, ion-channel-associated biology, and molecular substrates that may contribute to arrhythmogenic remodeling.
Explore interactions among obesity, diabetes, kidney disease, inflammation, oxidative stress, metabolic dysfunction, and cardiovascular remodeling.
The analytical platform should follow the analyte. Cardiovascular transcripts, circulating proteins, coagulation function, and imaging-derived phenotypes are different biological measurements and should not be treated as substitutes for one another.
Best suited for: targeted cardiovascular gene-expression and selected nucleic-acid research.
Development principle: follow MIQE 2.0 for preanalytics, assay specificity, reverse transcription, amplification efficiency, controls, normalization, analytical range, data analysis, and transparent reporting.
Best suited for: focused quantitative measurement of individual circulating or experimental protein biomarkers.
Development principle: use fit-for-purpose ligand-binding validation covering working range, precision, selectivity, dilutional parallelism, matrix effects, recovery where meaningful, stability, and lot performance.
Best suited for: simultaneous measurement of multiple cytokines, chemokines, growth factors, and soluble cardiovascular or inflammatory proteins.
Development principle: validate each analyte in the multiplex context. Dynamic range, minimum required dilution, matrix interference, parallelism, cross-talk, stability, lot/vendor effects, and inter-run variability can differ among analytes.
These examples illustrate research architecture rather than fixed diagnostic panels. Target selection should be justified for the disease model, specimen, biological question, and analytical platform.
Some of the best-known cardiovascular biomarkers are measured as circulating proteins. Their corresponding gene transcripts can be useful for mechanistic research, but they do not reproduce validated protein assays or clinical biomarker frameworks.
| Example | Research Interpretation | Important Limitation |
|---|---|---|
| NPPB / BNP pathway | NPPB transcript research can investigate natriuretic-peptide gene regulation in cells or tissues. | NPPB mRNA is not equivalent to circulating BNP or NT-proBNP protein measurement. |
| NPPA / ANP pathway | NPPA transcript abundance can support cardiac-stress or developmental/remodeling studies. | Transcript levels do not directly quantify circulating ANP peptide concentration. |
| GDF15 | GDF15 RNA or protein can be studied as a stress-associated biomarker depending on the question. | GDF15 is not specific to one cardiovascular disease and should be interpreted in biological context. |
| Troponin biology | TNNT2 or other sarcomeric transcripts may support structural or cardiomyocyte research. | TNNT2 transcript measurement is not equivalent to circulating cardiac troponin protein assays used to assess myocardial injury. |
| VWF / coagulation-associated genes | Transcript studies can investigate endothelial or coagulation-associated molecular responses. | Gene expression is not a substitute for functional coagulation, platelet, fibrinolytic, or circulating-protein assays. |
A defensible cardiovascular biomarker program should be fit for purpose. Analytical validation should match how the data will be used, and claims should remain limited to the specimen, platform, disease context, and endpoint actually evaluated.
| Stage | Best-Practice Approach | Scientific Rationale |
|---|---|---|
| 1. Define intended research use | Specify cardiovascular condition/model, pathway, analyte, specimen, intervention, comparator, timing, and endpoint. | Determines whether transcript, protein, or combined measurement is appropriate. |
| 2. Select biomarkers mechanistically | Use established cardiovascular biology, authoritative literature, discovery data, and prespecified hypotheses. | Mechanistic selection is more interpretable than assembling markers solely because they are measurable. |
| 3. Match analyte to technology | Use RT-qPCR for transcripts, ELISA for focused proteins, and bead-based multiplex assays for multianalyte soluble-protein research. | mRNA and protein values can diverge due to transcription, translation, secretion, turnover, cell source, and tissue compartment. |
| 4. Define sample context | Distinguish tissue, cultured cells, whole blood, PBMCs, plasma, serum, or other matrices and control preanalytical handling. | Cardiac tissue, vascular tissue, blood cells, and circulating proteins represent different biological compartments. |
| 5. Characterize analytical performance | Evaluate platform-specific specificity, precision, range, efficiency, matrix effects, interference, stability, and multiplex compatibility as appropriate. | Reduces the risk that technical effects are interpreted as cardiovascular biology. |
| 6. Establish controls & normalization | Use platform-appropriate negative, positive, process, calibration, and QC materials; validate reference-gene stability for RT-qPCR. | Controls should address actual failure modes of the assay and specimen matrix. |
| 7. Verify biologically | Use appropriate comparator groups, biological replication, longitudinal sampling, and prespecified analysis where relevant. | Cardiovascular biomarkers are influenced by age, renal function, metabolic state, inflammation, treatment, tissue injury, and sampling time. |
| 8. Validate independently | Lock candidate signatures or models and evaluate them in independent samples before broader generalization. | The 2026 AHA scientific statement on novel cardiovascular biomarkers emphasizes rigorous evaluation before biomarkers or models are considered clinically useful. |
Cardiovascular biomarker research requires careful separation of molecular association, tissue biology, circulating-protein concentration, functional physiology, and clinical utility.
AHA's 2026 scientific statement on cardiovascular biomarkers emphasizes that statistical association alone is not sufficient to establish predictive or clinical utility. Biomarkers must demonstrate appropriate analytical validity, incremental value, calibration, discrimination, reproducibility, and relevance to the intended use.
Therefore: IMDNA positions these assays for mechanistic, biomarker, pathway, and translational cardiovascular research—not as universal diagnostic, prognostic, or clinical risk-prediction tools.
A rigorous cardiovascular assay program connects disease mechanism, specimen choice, biomarker selection, technology, analytical validation, biological verification, and independent confirmation.
Each technology requires its own validation strategy. RT-qPCR/qPCR should follow current MIQE guidance; ELISA requires fit-for-purpose ligand-binding characterization; and multiplex bead assays require analyte-level validation and standardized execution.
Define collection, tissue handling, anticoagulant/matrix, processing interval, storage, extraction, freeze-thaw exposure, and relevant clinical/research covariates.
Evaluate specificity, amplification efficiency, analytical range, reverse transcription, controls, and normalization for the intended sample type.
Assess working range, precision, selectivity, matrix effects, parallelism/recovery where meaningful, stability, and lot performance.
Evaluate analyte-specific ranges, matrix sensitivity, cross-talk, parallelism, protocol dependence, low-end variability, and batch performance.
Use platform-specific controls and validate reference genes rather than assuming constitutive stability across ischemic, inflammatory, hypertrophic, or treatment conditions.
Confirm important findings by complementary methods when appropriate and test candidate signatures outside the discovery dataset.
Cardiovascular research rarely fits a universal panel. IMDNA can develop integrated research solutions using RT-qPCR/qPCR, ELISA, multiplex bead-based immunoassays, or a scientifically justified combination of these technologies.
Whether your work focuses on atherosclerosis, myocardial injury, heart failure, hypertension, cardiomyopathy, endothelial dysfunction, vascular inflammation, fibrosis, oxidative stress, angiogenesis, thrombosis-associated pathways, cardiometabolic biology, biomarker discovery, or experimental treatment response, IMDNA can develop a focused molecular and protein research strategy around your biological question.